Serum amphiregulin and mesothelin in auxiliary diagnosis of breast cancer

doi:10.3969/j.issn.1673-8640.2024.01.005

Abstract

Abstract:

Objective To investigate the roles of serum amphiregulin（AREG） and mesothelin（MSLN） levels in the auxiliary diagnosis of breast cancer. Methods A total of 54 female patients with breast cancer（breast cancer group），38 patients with benign breast lesions（benign lesion group） and 35 apparently healthy subjects（healthy control group） were enrolled from the Cancer Hospital of Fudan University from December 2018 to May 2019. Serum AREG and MSLN levels were determined by enzyme-linked immunosorbent assay. The relationship between serum AREG and MSLN levels and clinicopathological characteristics of breast cancer patients was analyzed. The efficacy of AREG and MSLN alone and in combination with carcinoembryonic antigen（CEA） and carbohydrate antigen（CA）15-3 in the auxiliary diagnosis of breast cancer was evaluated by receiver operating characteristic（ROC） curve. Results Compared with healthy control group，serum AREG and MSLN levels in breast cancer group were increased（P<0.05）. The areas under curves（AUC） of AREG and MSLN in the diagnosis of breast cancer were 0.582 and 0.637，respectively，while the AUC of serum AREG and MSLN combined with CEA and CA15-3 was 0.757. Serum AREG and MSLN levels in breast cancer group were related with pathological types and lymphatic metastasis（P<0.05）. Conclusions Serum AREG，MSLN combined with CEA and CA15-3 can play a role in the auxiliary diagnosis of breast cancer.

Key words: Amphiregulin, Mesothelin, Breast cancer

CLC Number:

R446.1

LIU Bohan, LIU Yiwen, HE Yiqing, LU Renquan, DU Yan, ZHANG Guoliang, GUO Qian, GAO Feng, YANG Cuixia. Serum amphiregulin and mesothelin in auxiliary diagnosis of breast cancer[J]. Laboratory Medicine, 2024, 39(1): 26-30.

Figures/Tables 6

References 19

[1]	BURSTEIN H J, CURIGLIANO G, THÜRLIMANN B, et al. Customizing local and systemic therapies for women with early breast cancer:the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021[J]. Ann Oncol, 2021, 32(10):1216-1235. DOI URL
[2]	JIA L, LI G, MA N, et al. Soluble POSTN is a novel biomarker complementing CA153 and CEA for breast cancer diagnosis and metastasis prediction[J]. BMC Cancer, 2022, 22(1):760. DOI PMID
[3]	SINGH S S, CHAUHAN S B, KUMAR A, et al. Amphiregulin in cellular physiology,health,and disease:potential use as a biomarker and therapeutic target[J]. J Cell Physiol, 2022, 237(2):1143-1156. DOI URL
[4]	NAGATHIHALLI N S, CASTELLANOS J A, LAMICHHANE P, et al. Inverse correlation of STAT3 and MEK signaling mediates resistance to RAS pathway inhibition in pancreatic cancer[J]. Cancer Res, 2018, 78(21):6235-6246. DOI PMID
[5]	XIANG G, LIU F, LIU J, et al. Prognostic role of amphiregulin and the correlation with androgen receptor in invasive breast cancer[J]. Pathol Res Pract, 2019, 215(6):152414. DOI URL
[6]	BOLITHO C, MOSCOVA M, BAXTER R C, et al. Amphiregulin increases migration and proliferation of epithelial ovarian cancer cells by inducing its own expression via PI3-kinase signaling[J]. Mol Cell Endocrinol, 2021, 533:111338. DOI URL
[7]	WANG Y, TZENG Y T, CHANG G, et al. Amphiregulin retains ERα expression in acquired aromatase inhibitor resistant breast cancer cells[J]. Endocr Relat Cancer, 2020, 27(12):671-683. DOI URL
[8]	WANG S F, CHANG Y L, TZENG Y D, et al. Mitochondrial stress adaptation promotes resistance to aromatase inhibitor in human breast cancer cells via ROS/calcium up-regulated amphiregulin-estrogen receptor loop signaling[J]. Cancer Lett, 2021, 523:82-99. DOI URL
[9]	XU Q, LONG Q, ZHU D, et al. Targeting amphiregulin(AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand(PD-L1)-mediated immunosuppression[J]. Aging Cell, 2019, 18(6):e13027. DOI URL
[10]	SCHMUCKER H, BLANDING W M, MOOK J M, et al. Amphiregulin regulates proliferation and migration of HER2-positive breast cancer cells[J]. Cell Oncol(Dordr), 2018, 41(2):159-168.
[11]	CHANG K, PASTAN I. Molecular cloning of mesothelin,a differentiation antigen present on mesothelium,mesotheliomas,and ovarian cancers[J]. Proc Natl Acad Sci U S A, 1996, 93(1):136-140. DOI URL
[12]	ATAY S. Integrated transcriptome meta-analysis of pancreatic ductal adenocarcinoma and matched adjacent pancreatic tissues[J]. PeerJ, 2020, 8:e10141. DOI URL
[13]	汪莉, 吴焕文, 梁智勇. 双向调节蛋白与肿瘤的相关性研究进展[J]. 临床与病理杂志, 2016, 1:71-75.
[14]	HE X, WANG L, RIEDEL H, et al. Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells[J]. Mol Cancer, 2017, 16(1):63. DOI PMID
[15]	BERASAIN C, AVILA M A. Amphiregulin[J]. Semin Cell Dev Biol, 2014, 28:31-41. DOI PMID
[16]	MADEIRA K, DONDOSSOLA E R, FARIAS B F, et al. Mesothelin as a biomarker for ovarian carcinoma:a meta-analysis[J]. An Acad Bras Cienc, 2016, 88(2):923-932. DOI URL
[17]	TAKIHATA Y, EINAMA T, KOBAYASHI K, et al. Different role of MSLN and CA125 co-expression as a prognostic predictor between perihilar and distal bile duct carcinoma[J]. Oncol Lett, 2021, 21(5):414. DOI PMID
[18]	CHAYANGSU C, KHUNSRI S, SRIURANPONG V, et al. The correlations between serum amphiregulin and other clinicopathological factors in colorectal cancer[J]. J Gastrointest Oncol, 2017, 8(6):980-984. DOI PMID
[19]	MELDERIS S, WARKOTSCH M T, DANG J, et al. The amphiregulin/EGFR axis protects from lupus nephritis via downregulation of pathogenic CD4+ T helper cell responses[J]. J Autoimmun, 2022, 129:102829. DOI URL

组别	例数	AREG/（ng·mL^-1）	MSLN/（ng·mL^-1）
健康对照组	35	219.8±81.2	0.425 1±0.234 0
良性病变组	38	274.6±93.8	0.481 4±0.244 5
乳腺癌组	54	318.6±106.4^*	0.561 9±0.313 6^*#

组别	例数	AREG/（ng·mL^-1）	MSLN/（ng·mL^-1）
健康对照组	35	219.8±81.2	0.425 1±0.234 0
良性病变组	38	274.6±93.8	0.481 4±0.244 5
乳腺癌组	54	318.6±106.4^*	0.561 9±0.313 6^*#

项目	敏感性/%	特异性/%	AUC（95%可信区间）
AREG	72	56	0.582（0.453~0.710）
MSLN	51	66	0.637（0.513~0.760）
CEA	76	68	0.657（0.541~0.773）
CA15-3	57	71	0.571（0.459~0.704）
联合检测	66	81	0.757（0.649~0.865）

项目	敏感性/%	特异性/%	AUC（95%可信区间）
AREG	72	56	0.582（0.453~0.710）
MSLN	51	66	0.637（0.513~0.760）
CEA	76	68	0.657（0.541~0.773）
CA15-3	57	71	0.571（0.459~0.704）
联合检测	66	81	0.757（0.649~0.865）

临床病理特征	例数	AREG/ （ng·mL^-1）	MSLN/ （ng·mL^-1）	临床病理特征	例数	AREG/ （ng·mL^-1）	MSLN/ （ng·mL^-1）
年龄				淋巴转移
<50岁	24	121.0±80.6	0.38（0.29，0.50）	有	16	321.7±114.1	0.50（0.34，0.89）
≥50岁	30	295.0±256.8	0.39（0.28，0.39）	无	38	256.0±95.9	0.33（0.27，0.43）
P值		0.060 0	0.644 0	P值		0.037 8	0.022 4
病理类型				雌激素受体
原位癌	17	269.5±70.2	0.32（0.29，0.48）	阳性	32	278.6±94.2	0.37（0.30，0.55）
浸润性癌	37	352.2±102.8	0.67（0.40，0.93）	阴性	22	283.9±147.2	0.39（0.26，0.62）
P值		0.006 1	0.006 0	P值		0.886 4	0.764 1
脉管侵犯				孕激素受体
无	35	272.3±91.3	0.38（0.28，0.62）	阳性	29	285.5±92.9	0.39（0.32，0.62）
有	19	287.1±125.6	0.43（0.32，0.67）	阴性	25	261.7±141.6	0.36（0.28，0.59）
P值		0.591 8	0.497 4	P值		0.592 1	0.512 4
TNM分期				人表皮生长因子受体2
Ⅰ~Ⅱ期	30	272.3±91.3	0.39（0.25，0.50）	0	8	275.2±50.3	0.38（0.26，0.62）
Ⅲ~Ⅳ期	24	287.1±125.6	0.39（0.30，0.70）	+	26	279.3±89.9	0.39（0.29，0.51）
P值		0.633 3	0.399 4	++	9	289.5±90.1	0.48（0.31，0.73）
				+++	11	282.2±72.7	0.38（0.25，0.86）
				P值		0.409 8	0.928 4